Zydus has solidified its position in the global biologics market through the acquisition of Agenus, which includes biologics manufacturing sites in Emeryville and Berkeley, California. The deal involves an upfront payment of $75 million, with an additional $50 million in milestone-based payments over three years. These facilities will support Zydus’ new biologics CDMO business, catering to biotech and pharma firms worldwide looking for end-to-end development and manufacturing solutions.
This strategic move not only expands Zydus’ capabilities in biologics manufacturing but also enhances its competitiveness in the rapidly growing biotech sector. With a focus on immuno-oncology and cutting-edge biologics, Zydus is poised to meet the increasing demand for innovative therapies. The acquisition positions Zydus as a key player in the biologics market, poised for further growth and collaboration in the evolving landscape of biopharmaceuticals.
Read more from fortuneindia.com
